Sunesis Pharmaceuticals, Inc.  

(Public, NASDAQ:SNSS)   Watch this stock  
Find more results for SNSS
4.44
0.00 (0.00%)
Sep 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 2.63 - 6.78
Open     -
Vol / Avg. 0.00/167,184.00
Mkt cap 63.25M
P/E     -
Div/yield     -
EPS -2.89
Shares 14.50M
Beta 1.77
Inst. own 59%
Nov 3, 2016
Q3 2016 Sunesis Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Sep 13, 2016
Sunesis Pharmaceuticals Inc at Rodman & Renshaw Global Investment Conference
Sep 12, 2016
Sunesis Pharmaceuticals, Inc. Preliminary Results From the Oral Non-Covalent BTK-inhibitor SNS-062 Call - Webcast
Sep 7, 2016
Sunesis Pharmaceuticals Inc at Wells Fargo Securities Healthcare Conference
Jul 29, 2016
Q2 2016 Sunesis Pharmaceuticals Inc Earnings Call
Jul 29, 2016
Q2 2016 Sunesis Pharmaceuticals Inc Earnings Release
Jul 12, 2016
Sunesis Pharmaceuticals Inc at Cantor Fitzgerald Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -1712.46% -1198.17%
Operating margin -1638.20% -1283.96%
EBITD margin - -1283.08%
Return on average assets -112.20% -80.39%
Return on average equity - -296.54%
Employees 38 -
CDP Score - -

Address

395 Oyster Point Blvd Ste 400
SOUTH SAN FRANCISCO, CA 94080-1995
United States - Map
+1-650-2663500 (Phone)
+1-650-2663501 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD). The Company's other kinase inhibitor pipeline include TAK-580, SNS-062 and SNS-229. TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. SNS-062 is a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK). The Company has completed the pre-clinical studies for SNS-062. SNS-229 and SNS-510 are two PDK1 inhibitors. PDK1 is a kinase and mediator of Phosphoinositide 3-kinase/AKT (PI3K/AKT) signaling, which is a pathway involved in cell growth, differentiation, survival and migration.

Officers and directors

Daniel N. Swisher Jr. President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Eric H. Bjerkholt Chief Financial Officer, Executive Vice President - Corporate Development and Finance
Age: 56
Bio & Compensation  - Reuters
Adam R. Craig M.D. Ph.D. Executive Vice President - Development, Chief Medical Officer
Age: 50
Bio & Compensation  - Reuters
James W. Young Ph.D. Non-Executive Independent Chairman of the Board
Bio & Compensation  - Reuters
Stephen B. Ketchum Ph.D. Director
Age: 50
Bio & Compensation  - Reuters
Geoffrey M. Parker Director
Age: 51
Bio & Compensation  - Reuters
Steve R. Carchedi Independent Director
Age: 53
Bio & Compensation  - Reuters
Matthew K. Fust Independent Director
Age: 50
Bio & Compensation  - Reuters